Larimar Therapeutics Inc (LRMR)

[FairviewInvestor]

Zafgen abandoned its lead drug, beloranib—an obesity treatment beset by safety problems—and will instead put its resources behind a follow-on preclinical obesity drug that it believes to be much safer. Xconomy spoke with CEO Tom Hughes about the decision, which is terrible news for patients with the rare disease Prader-Willi Syndrome; Zafgen had hoped to win FDA approval of beloranib in Prader-Willi, which would have made it the first marketed drug for the disease since human growth hormone over a decade ago. Shares of Zafgen fell more than 50 percent on the news.


So basically.. any buying of stock here is pure speculation that they will come up with a new drug? and re-invent themselves as a company. Crystal Ball sees a capital raise in future ?